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Dear Editor:
We read with considerable interest the paper by Gomez Font 
et al. summarizing the latest information on bisphosphonate 
related osteochemonecrosis of the jaws (BON)(1). 
The authors note that risk factors associated with osteochemo-
necrosis due to bisphosphonates are diverse. They report drug 
type, doses and means of administration, treatment duration, 
mucosal trauma, dentoalveolar surgery, smoking, and diabetes 
mellitus to be associated with the disease(1). A recent study 
even reports a surrogate biomarker; CTX terminal telopeptide 
serum levels as the authors state(1). In this regard we have 
carried out the first case control study addressing potential 
risk factors for ONJ development in breast cancer patients(2). 
In this study we report statistically significant risk factors 
for BON development among breast cancer patients under 
zoledronic acid (ZA) medication(2) .
An issue that remains to be elucidated is potency of BP 
medication. All patients included in our study (2) received 
ZA which is considered to be the most potent osteoclast 
inhibitor(3). Since our study was a matched case control we 
were not able to explore the potential influence of drug type, 
doses and administration way in the development of BON. 
However, we believe that other drugs, i.e. ibandronate are less 
effective in causing BON, also based on still unpublished data 
of ours(2). Further studies are needed to clarify administered 
drug type as a potential risk factor. 
Treatment duration is probably a risk factor, which we also 
preferred not to explore in a matched design. It is probable 
that longer ZA treatment predisposes to ONJ(4). Of note we 
preferred not to test treatment duration as an independent risk 
factor since our aim was to detect prognostic factors to avoid 
BON and not to propose reducing ZA doses as a preventive 
measure(2).
The authors point out that bisphosphonates also produce an 
inhibitory effect on the keratinocyte cellular cycle, which 
hinders the habitual mucous repair mechanisms(1). A quite 
recent study adds to this, for the first time providing evidence 
that mucosal wound healing could be impaired(5). What is 
more these authors demonstrated that increased apoptosis 
–programmed cell death- is not likely to contribute to this 
effect(5). Mucosal trauma resulting from ill-fitting dentures 
could be the reason for increased risk for BON among these 
patients demonstrated by our study(2).
Dentoalveolar trauma is considered to influence the develo-
pment of BON(1). Our study found a sixteen times higher 
relative risk for BON development among patients who had 
experienced tooth extraction during ZA treatment(2).
Smoking and endodontic treatment were not found to be 
independent risk factors. However smoking is a known risk 
factor for breast cancer(6), and the probability that it might 
be a confounding or effect modifying factor cannot be dimi-
nished with regard to our study(2).
The authors adopt the treatment protocol firstly proposed by 
Woo et al.(7). Nevertheless this protocol was argued since it 
was not based on knowledge about the pathobiology of ONJ, 
nor was it evidence based (5, 8, 9). Our study (2) provides cli-
nical evidence that BON is associated with tooth extractions 
and overdentures but not with endodontic treatment, currently 
updating the ASCO level of evidence from V to III. In this 
regard we support the protocol proposed by Woo et al.(7) 
also adopted by Gomez Font et al.(1) with the exception of 
endodontic treatment which we consider to be a safe choice 
for these patients(2).
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